Short answer
ALUMIS INC. (ALMS) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $2M (down 37.7% year over year) with net income of −$142M.
Q2 2026 key financials · XBRL
- Revenue
- $2M
- −37.7% YoY · −4.5% QoQ
- Net income
- −$142M
- −339.7% YoY · −52.8% QoQ
- Operating margin
- -8956.4%
- EPS (diluted)
- −$1.12
- −192.6% YoY · −51.4% QoQ
Source: XBRL data from the ALUMIS INC. (ALMS) Q2 2026 10-Q on SEC EDGAR. USD.
ALUMIS INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no products approved or product-sales revenue
- Net loss $142.2M vs $59.3M net income YoY
- Accumulated deficit $1,137.2M as of June 30, 2026
- Operating cash flow remained negative; January offering generated $324.4M net proceeds
- Envu NDA submission planned Q4 2026; SLE topline results expected Q3 2026
Risk Factors
- No explicit “no material changes” statement; latest filing identifies no clearly new risk trigger versus the 10-K
- Financing risk: March 2026 Cantor Sales Agreement permits up to $300.0 million in common-stock offerings
- Clinical enrollment risk: Phase 2b SLE trial requires active disease at screening, making recruitment challenging
- Regulatory risk: FDA or foreign regulators may impose clinical holds for protocol, safety, GCP, or funding deficiencies
- Financial risk: Accumulated deficit reached $1,137.2 million as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ALUMIS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.